The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.

Stanford is now accepting new patients for this trial. Please contact Maria Perlas at 650-723-2094 for more information.



  • device : Renal denervation (Symplicity Catheter System)

Phase: Phase 3


Ages Eligible For Study:

18 Years - 80 Years

Inclusion Criteria

- Individual is ? 18 and ? 80 years old at time of randomization. - Individual is receiving a stable medication regimen including full tolerated doses of 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic (with no changes for a minimum of 2 weeks prior to screening) that is expected to be maintained without changes for at least 6 months. - Individual has an office systolic blood pressure (SBP) of ? 160 mmHg based on an average of 3 blood pressure readings measured at both an initial screening visit and a confirmatory screening visit

External Links

Explore related trials

Contact information

Primary Contact:

Maria Perlas 650-723-2094

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: